# Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR

Study · id `cardio:ct-nct06763744` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06763744](<https://clinicaltrials.gov/study/NCT06763744>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06763744

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3000 participants.

## Technical summary

Registry record NCT06763744. Randomized; no masking; primary purpose treatment. Start 2025-06-01 (anticipated); primary completion 2029-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3000 participants (planned count; ClinicalTrials.gov record NCT06763744, source copy `cardio:ctgov-nct06763744-2025-05-18`, retrieved 2026-10-31)
- Planned start: 2025-06-01 (anticipated) (ClinicalTrials.gov record NCT06763744, source copy `cardio:ctgov-nct06763744-2025-05-18`, retrieved 2026-10-31)
- Primary completion: 2029-07-31 (anticipated) (ClinicalTrials.gov record NCT06763744, source copy `cardio:ctgov-nct06763744-2025-05-18`, retrieved 2026-10-31)
- Completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT06763744, source copy `cardio:ctgov-nct06763744-2025-05-18`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT06763744, source copy `cardio:ctgov-nct06763744-2025-05-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06763744-2025-05-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
- Acronym: GUIDE-HBR
- Condition: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
- Condition: High Bleeding Risk
- Intervention (Drug): P2Y12 antagonist monotherapy
- Intervention (Drug): clopidogrel + aspirin
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

## Provenance

Content hash: ed39e45cac120a9c79c14b5956a75ca50fa29d41263f37f51d81374d9a85b770
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
